Alto Neuroscience (NYSE:ANRO – Get Free Report) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Thursday,Zacks.com reports.
Several other equities research analysts have also recently commented on the stock. HC Wainwright lifted their price target on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 17th. Wolfe Research began coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Robert W. Baird reduced their price objective on shares of Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Bank of America assumed coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Finally, Wall Street Zen raised Alto Neuroscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Alto Neuroscience currently has a consensus rating of “Moderate Buy” and an average target price of $37.25.
Check Out Our Latest Stock Report on ANRO
Alto Neuroscience Trading Up 0.3%
Alto Neuroscience (NYSE:ANRO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.08. As a group, research analysts predict that Alto Neuroscience will post -2.68 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of ANRO. Commodore Capital LP acquired a new position in Alto Neuroscience during the fourth quarter valued at approximately $32,453,000. Perceptive Advisors LLC boosted its position in shares of Alto Neuroscience by 1,048.5% during the fourth quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock worth $31,762,000 after purchasing an additional 1,629,027 shares in the last quarter. Vestal Point Capital LP boosted its position in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after purchasing an additional 1,535,000 shares in the last quarter. Spruce Street Capital LP grew its holdings in shares of Alto Neuroscience by 494.7% in the 1st quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after buying an additional 1,102,366 shares during the period. Finally, Vivo Capital LLC acquired a new position in shares of Alto Neuroscience in the 4th quarter valued at $18,433,000.
Alto Neuroscience Company Profile
Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.
Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
